962 related articles for article (PubMed ID: 33573699)
21. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
22. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
[TBL] [Abstract][Full Text] [Related]
23. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
[TBL] [Abstract][Full Text] [Related]
24. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Arabi YM; Gordon AC; Derde LPG; Nichol AD; Murthy S; Beidh FA; Annane D; Swaidan LA; Beane A; Beasley R; Berry LR; Bhimani Z; Bonten MJM; Bradbury CA; Brunkhorst FM; Buxton M; Buzgau A; Cheng A; De Jong M; Detry MA; Duffy EJ; Estcourt LJ; Fitzgerald M; Fowler R; Girard TD; Goligher EC; Goossens H; Haniffa R; Higgins AM; Hills TE; Horvat CM; Huang DT; King AJ; Lamontagne F; Lawler PR; Lewis R; Linstrum K; Litton E; Lorenzi E; Malakouti S; McAuley DF; McGlothlin A; Mcguinness S; McVerry BJ; Montgomery SK; Morpeth SC; Mouncey PR; Orr K; Parke R; Parker JC; Patanwala AE; Rowan KM; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Tong SYC; Turgeon AF; Turner AM; Van de Veerdonk FL; Zarychanski R; Green C; Berry S; Marshall JC; McArthur C; Angus DC; Webb SA;
Intensive Care Med; 2021 Aug; 47(8):867-886. PubMed ID: 34251506
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
[TBL] [Abstract][Full Text] [Related]
26. In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
Singh A
Ann Intern Med; 2021 Jan; 174(1):JC3. PubMed ID: 33395331
[TBL] [Abstract][Full Text] [Related]
27. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.
Nojomi M; Yassin Z; Keyvani H; Makiani MJ; Roham M; Laali A; Dehghan N; Navaei M; Ranjbar M
BMC Infect Dis; 2020 Dec; 20(1):954. PubMed ID: 33317461
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
30. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
[TBL] [Abstract][Full Text] [Related]
31. Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
Mazaherpour H; Sofian M; Farahani E; Abdi A; Mazaherpour S; Bavand A; Ramezani A
Biomed Res Int; 2022; 2022():1522426. PubMed ID: 35013710
[TBL] [Abstract][Full Text] [Related]
32. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
[TBL] [Abstract][Full Text] [Related]
33. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 in hospitalised patients in Spain: a cohort study in Madrid.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Valerio M; Amor-Garcia MA; Tejerina F; Sancho-Gonzalez M; Narrillos-Moraza A; Gimenez-Manzorro A; Manrique-Rodriguez S; Machado M; Olmedo M; Escudero-Vilaplana V; Villanueva-Bueno C; Torroba-Sanz B; Melgarejo-Ortuño A; Vicente-Valor J; Herranz A; Bouza E; Muñoz P; Sanjurjo M
Int J Antimicrob Agents; 2021 Feb; 57(2):106249. PubMed ID: 33259918
[TBL] [Abstract][Full Text] [Related]
35. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
[TBL] [Abstract][Full Text] [Related]
36. High-dose intravenous vitamin C decreases rates of mechanical ventilation and cardiac arrest in severe COVID-19.
Hess AL; Halalau A; Dokter JJ; Paydawy TS; Karabon P; Bastani A; Baker RE; Balla AK; Galens SA
Intern Emerg Med; 2022 Sep; 17(6):1759-1768. PubMed ID: 35349005
[TBL] [Abstract][Full Text] [Related]
37. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
38. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
39. An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.
Ader F;
Clin Microbiol Infect; 2022 Sep; 28(9):1293-1296. PubMed ID: 35533972
[No Abstract] [Full Text] [Related]
40. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
